Acadia announces positive results of Phase 3 trial to treat psychosis
Category: #health  By Pankaj Singh  Date: 2019-12-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

Acadia announces positive results of Phase 3 trial to treat psychosis

Acadia Pharmaceuticals, a renowned US-based biopharmaceutical company dedicated to the development of treatments for central nervous system disorders, reportedly announced positive outcomes from its Phase 3 HARMONY study of pimavanserin.

The company announced these positive outcomes during the 12th CTAD (Clinical Trials on Alzheimer’s Disease) meeting being held in San Diego, California between December 4 and 7, 2019.

HARMONY was a relapse prevention, double-blind, placebo-controlled trial in 392 patients for the evaluation of pimavanserin to treat dementia-related psychosis.

Director Emeritus of Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Jeffrey Cummings, M.D., Sc.D. stated that the outcomes showcased are a crucial advancement for caregivers and patients who struggle with the weight of dementia-related psychosis, a niche where there is no FDA-approved therapy currently available.  

Cummings further added that decreasing the threat of relapse of psychotic symptoms with this margin is a vital and meaningful result. This is because these are very serious events that could further lead to poor patient results and substantial growth in caregiver distress and burden.

The Phase 3 HARMONY trial comprised a 12-week open-label pimavanserin therapy period before the randomization period of the trial. During this open-label therapy period, 61.8% of eligible patients were able to reach to pre-specified criteria for pimavanserin therapy response at week 12 and week 8 both.

For patients in the open-label therapy period, alteration from baseline to week 8 and then to week 12 on the SAPS-H+D (Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions) score increased by 63.0% as well as 75.2% respectively.

President of ACADIA, Serge Stankovic, M.D., M.S.P.H., stated that the company is thrilled to unveil the top-line outcomes from this Phase 3 study to treat dementia-related psychosis. The HARMONY trial was innovated to get solutions for three very important problems. First, during the 12-week open-label period, treatment through pimavanserin indicated a meaningful decrease of the symptoms. Also, a reduction in the stabilization of psychosis through all the five clinically detected subtypes evaluated were seen.

Second, during the 26-week double-blind timeframe, patients dosed with pimavanserin had an almost three-fold decrease in risk of relapse in comparison with patients on placebo. Third, elderly patients suffering from dementia-related psychosis could tolerate pimavanserin well.

The company looks forward to discussing these outcomes with the FDA in the first half of the coming year.

 

 

Source credit: https://ir.acadia-pharm.com/news-releases/news-release-details/acadia-pharmaceuticals-presents-positive-top-line-results?field_nir_news_date_value%5bmin%5d=



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

CDE of China NMPA clears I-Mab’s application for lemzoparlimab
CDE of China NMPA clears I-Mab’s application for lemzoparlimab
By Pankaj Singh

Clinical stage biopharmaceutical major, I-Mab, has reportedly announced that it has received the clearance of the Center for Drug Evaluation of the China National Medical Products Administration for its IND application...

Aoyuan Healthy to acquire 55% equity interest in Liantianmei
Aoyuan Healthy to acquire 55% equity interest in Liantianmei
By Pankaj Singh

Aoyuan Healthy Life Group Company Ltd., a renowned commercial property operation service and property management service provider based in China, has reportedly announced that Guangdong Xinyuerong Industrial Investment...

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...